Repurposing anti-diabetic drug "Sitagliptin" as a novel virulence attenuating agent in Serratia marcescens.
Anti-Bacterial Agents
/ pharmacology
Biofilms
/ drug effects
Cross Infection
/ drug therapy
Drug Repositioning
Humans
Hypoglycemic Agents
/ pharmacology
Quorum Sensing
/ drug effects
Serratia Infections
/ drug therapy
Serratia marcescens
/ drug effects
Sitagliptin Phosphate
/ pharmacology
Virulence
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
12
2019
accepted:
26
03
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Serratia marcescens is an emerging pathogen that causes a variety of health care associated infections. S. marcescens is equipped with an arsenal of virulence factors such as biofilm formation, swimming and swarming motilities, prodigiosin, protease and others which enable it to initiate and cause the infection. These virulence factors are orchestrated under the umbrella of an intercellular communication system named Quorum sensing (QS). QS allows bacterial population to synchronize the expression of virulence genes upon detection of a chemical signaling molecule. Targeting bacterial virulence is a promising approach to attenuate bacteria and enhances the ability of immune system to eradicate the bacterial infection. Drug repurposing is an advantageous strategy that confers new applications for drugs outside the scope of their original medical use. This promising strategy offers the use of safe approved compounds, which potentially lowers the costs and shortens the time than that needed for development of new drugs. Sitagliptin is dipeptidyl peptidase-4 (DPP-4) inhibitor, is used to treat diabetes mellitus type II as it increases the production of insulin and decreasing the production of glucagon by the pancreas. We aimed in this study to repurpose sitagliptin, investigating the anti-virulence activities of sitagliptin on S. marcescens. The effect of sub-inhibitory concentrations of sitagliptin on virulence factors; protease, prodigiosin, biofilm formation, swimming and swarming motilities was estimated phenotypically. The qRT-PCR was used to show the effect of sitagliptin on the expression of QS-regulated virulence genes. The in-vivo protective activity of sitagliptin on S. marcescens pathogenesis was evaluated on mice. Sitagliptin (1 mg/ml) significantly reduced the biofilm formation, swimming and swarming motilities, prodigiosin and protease. The qRT-PCR confirmed the effect on virulence as shown by down regulating the expression of fimA, fimC, flhC, flhD, bsmB, rssB, rsmA, pigP, and shlA genes. Moreover, the in-vivo findings showed the efficient ability of sitagliptin to weaken S. marcescens pathogenesis. Sitagliptin is a promising anti-virulence agent against S. marcescens that may be beneficial in the control of healthcare associated infections caused by S. marcescens.
Sections du résumé
BACKGROUND
Serratia marcescens is an emerging pathogen that causes a variety of health care associated infections. S. marcescens is equipped with an arsenal of virulence factors such as biofilm formation, swimming and swarming motilities, prodigiosin, protease and others which enable it to initiate and cause the infection. These virulence factors are orchestrated under the umbrella of an intercellular communication system named Quorum sensing (QS). QS allows bacterial population to synchronize the expression of virulence genes upon detection of a chemical signaling molecule. Targeting bacterial virulence is a promising approach to attenuate bacteria and enhances the ability of immune system to eradicate the bacterial infection. Drug repurposing is an advantageous strategy that confers new applications for drugs outside the scope of their original medical use. This promising strategy offers the use of safe approved compounds, which potentially lowers the costs and shortens the time than that needed for development of new drugs. Sitagliptin is dipeptidyl peptidase-4 (DPP-4) inhibitor, is used to treat diabetes mellitus type II as it increases the production of insulin and decreasing the production of glucagon by the pancreas. We aimed in this study to repurpose sitagliptin, investigating the anti-virulence activities of sitagliptin on S. marcescens.
METHODS
The effect of sub-inhibitory concentrations of sitagliptin on virulence factors; protease, prodigiosin, biofilm formation, swimming and swarming motilities was estimated phenotypically. The qRT-PCR was used to show the effect of sitagliptin on the expression of QS-regulated virulence genes. The in-vivo protective activity of sitagliptin on S. marcescens pathogenesis was evaluated on mice.
RESULTS
Sitagliptin (1 mg/ml) significantly reduced the biofilm formation, swimming and swarming motilities, prodigiosin and protease. The qRT-PCR confirmed the effect on virulence as shown by down regulating the expression of fimA, fimC, flhC, flhD, bsmB, rssB, rsmA, pigP, and shlA genes. Moreover, the in-vivo findings showed the efficient ability of sitagliptin to weaken S. marcescens pathogenesis.
CONCLUSION
Sitagliptin is a promising anti-virulence agent against S. marcescens that may be beneficial in the control of healthcare associated infections caused by S. marcescens.
Identifiants
pubmed: 32298346
doi: 10.1371/journal.pone.0231625
pii: PONE-D-19-33885
pmc: PMC7162429
doi:
Substances chimiques
Anti-Bacterial Agents
0
Hypoglycemic Agents
0
Sitagliptin Phosphate
TS63EW8X6F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231625Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Genes Dev. 2007 Jan 15;21(2):221-33
pubmed: 17234887
Chemotherapy. 2000 Sep-Oct;46(5):315-21
pubmed: 10965096
Pathog Dis. 2015 Aug;73(6):ftv038
pubmed: 26013821
PLoS Pathog. 2017 Aug 23;13(8):e1006579
pubmed: 28832671
Ultrason Sonochem. 2017 May;36:343-353
pubmed: 28069219
Mol Microbiol. 2000 May;36(3):539-56
pubmed: 10844645
Cell. 2015 Jan 15;160(1-2):228-40
pubmed: 25579683
Front Endocrinol (Lausanne). 2019 Jun 19;10:376
pubmed: 31275243
Genome Announc. 2013 Aug 15;1(4):
pubmed: 23950115
World J Microbiol Biotechnol. 2019 Sep 6;35(9):143
pubmed: 31493142
J Med Microbiol. 2003 Jan;52(Pt 1):19-28
pubmed: 12488561
Curr Microbiol. 2020 Feb 4;:
pubmed: 32020464
Can J Microbiol. 2016 Jan;62(1):83-93
pubmed: 26640000
Genome Biol Evol. 2014 Aug;6(8):2096-110
pubmed: 25070509
Microbiology. 2006 Jul;152(Pt 7):1899-1911
pubmed: 16804166
ChemistryOpen. 2015 Aug;4(4):463-70
pubmed: 26478841
Biochem Biophys Res Commun. 2017 Jul 15;489(1):70-75
pubmed: 28522292
J Bacteriol. 1994 Jan;176(2):269-75
pubmed: 8288518
Mol Microbiol. 2003 Jan;47(2):303-20
pubmed: 12519208
Acta Biochim Biophys Sin (Shanghai). 2008 Dec;40(12):1023-8
pubmed: 19089300
Front Cell Infect Microbiol. 2017 Oct 12;7:441
pubmed: 29075619
Bioorg Med Chem. 2015 Apr 1;23(7):1638-50
pubmed: 25716005
Mol Microbiol. 1993 Nov;10(3):511-20
pubmed: 7968529
Res Microbiol. 2007 Mar;158(2):150-8
pubmed: 17258895
Mol Microbiol. 2002 Sep;45(6):1655-71
pubmed: 12354232
Eur J Med Chem. 2015 Sep 18;102:413-24
pubmed: 26301558
Front Microbiol. 2019 Jul 24;10:1715
pubmed: 31396200
Antimicrob Agents Chemother. 2008 Jan;52(1):198-203
pubmed: 17938186
Infect Immun. 2015 Nov;83(11):4373-82
pubmed: 26324535
Int J Environ Res Public Health. 2019 Feb 20;16(4):
pubmed: 30791509
Sci Rep. 2015 Mar 02;5:8656
pubmed: 25728862
J Biomed Sci. 2001 Mar-Apr;8(2):160-9
pubmed: 11287746
Front Cell Infect Microbiol. 2017 Dec 05;7:498
pubmed: 29259923
Antonie Van Leeuwenhoek. 2018 Apr;111(4):501-515
pubmed: 29101490
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Front Microbiol. 2019 Sep 03;10:2049
pubmed: 31551983
Science. 1998 Apr 10;280(5361):295-8
pubmed: 9535661
FEMS Microbiol Rev. 2007 Jul;31(4):407-24
pubmed: 17459113
Cell Microbiol. 2019 Sep;21(9):e13045
pubmed: 31099073
J Bacteriol. 2007 Oct;189(20):7262-72
pubmed: 17675374
J Bacteriol. 2017 Sep 5;199(19):
pubmed: 28484045
J Bacteriol. 1992 Mar;174(6):1769-76
pubmed: 1548227
Crit Rev Microbiol. 2011 May;37(2):121-40
pubmed: 21271798
J Ethnopharmacol. 2014 May 28;154(1):170-5
pubmed: 24742751
Proc Natl Acad Sci U S A. 1984 Jul;81(13):4154-8
pubmed: 6377310
Adv Microbiol. 2012 Dec 1;2(4):
pubmed: 24358451
Biotechnol Bioeng. 2016 Nov;113(11):2513-7
pubmed: 27217017
Heliyon. 2019 Aug 19;5(8):e02192
pubmed: 31463386
Molecules. 2018 May 04;23(5):
pubmed: 29734673
PLoS One. 2011;6(8):e24154
pubmed: 21887380
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7
pubmed: 20597676
Sci Rep. 2016 Nov 15;6:36747
pubmed: 27845335
Antimicrob Agents Chemother. 2006 May;50(5):1680-8
pubmed: 16641435
J Antimicrob Chemother. 2003 Apr;51(4):865-85
pubmed: 12654765
Arch Med Res. 2011 Nov;42(8):658-68
pubmed: 22222491
Lett Appl Microbiol. 2006 Jun;42(6):637-41
pubmed: 16706905
J Clin Microbiol. 2003 Oct;41(10):4726-32
pubmed: 14532211